315 related articles for article (PubMed ID: 31055836)
1. Antibodies against alpha-synuclein: tools and therapies.
Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA
J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
3. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.
Doucet M; El-Turabi A; Zabel F; Hunn BHM; Bengoa-Vergniory N; Cioroch M; Ramm M; Smith AM; Gomes AC; Cabral de Miranda G; Wade-Martins R; Bachmann MF
PLoS One; 2017; 12(8):e0181844. PubMed ID: 28797124
[TBL] [Abstract][Full Text] [Related]
4. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.
Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR
Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825
[TBL] [Abstract][Full Text] [Related]
5. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies.
Fayyad M; Majbour NK; Vaikath NN; Erskine D; El-Tarawneh H; Sudhakaran IP; Abdesselem H; El-Agnaf OMA
Neurosci Lett; 2020 Apr; 725():134899. PubMed ID: 32156613
[TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective.
Knecht L; Folke J; Dodel R; Ross JA; Albus A
Neurotherapeutics; 2022 Sep; 19(5):1489-1502. PubMed ID: 36083395
[TBL] [Abstract][Full Text] [Related]
7. In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies.
Marvian AT; Koss DJ; Aliakbari F; Morshedi D; Outeiro TF
J Neurochem; 2019 Sep; 150(5):535-565. PubMed ID: 31004503
[TBL] [Abstract][Full Text] [Related]
8. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
[TBL] [Abstract][Full Text] [Related]
9. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
[TBL] [Abstract][Full Text] [Related]
10. FKBP12-immunopositive inclusions in patients with α-synucleinopathies.
Honjo Y; Ayaki T; Horibe T; Ito H; Takahashi R; Kawakami K
Brain Res; 2018 Feb; 1680():39-45. PubMed ID: 29246765
[TBL] [Abstract][Full Text] [Related]
11. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.
Peng C; Gathagan RJ; Lee VM
Neurobiol Dis; 2018 Jan; 109(Pt B):209-218. PubMed ID: 28751258
[TBL] [Abstract][Full Text] [Related]
12. Binding Stability of Antibody-α-Synuclein Complexes Predicts the Protective Efficacy of Anti-α-synuclein Antibodies.
Höllerhage M; Wolff A; Chakroun T; Evsyukov V; Duan L; Chua OW; Tang Q; Koeglsperger T; Höglinger GU
Mol Neurobiol; 2022 Jul; 59(7):3980-3995. PubMed ID: 35460053
[TBL] [Abstract][Full Text] [Related]
13. Monitoring α-synuclein aggregation.
Estaun-Panzano J; Arotcarena ML; Bezard E
Neurobiol Dis; 2023 Jan; 176():105966. PubMed ID: 36527982
[TBL] [Abstract][Full Text] [Related]
14. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
15. Development of a Novel Electrochemiluminescence ELISA for Quantification of α-Synuclein Phosphorylated at Ser
Dutta S; Hornung S; Taha HB; Biggs K; Siddique I; Chamoun LM; Shahpasand-Kroner H; Lantz C; Herrera-Vaquero M; Stefanova N; Loo JA; Bitan G
ACS Chem Neurosci; 2023 Apr; 14(7):1238-1248. PubMed ID: 36920792
[TBL] [Abstract][Full Text] [Related]
16. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease.
Wang Z; Gao G; Duan C; Yang H
Biomed Pharmacother; 2019 Jul; 115():108843. PubMed ID: 31055236
[TBL] [Abstract][Full Text] [Related]
17. Novel antibodies to phosphorylated α-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes.
Rutherford NJ; Brooks M; Giasson BI
Acta Neuropathol Commun; 2016 Aug; 4(1):80. PubMed ID: 27503460
[TBL] [Abstract][Full Text] [Related]
18. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
[TBL] [Abstract][Full Text] [Related]
19. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions.
Waxman EA; Duda JE; Giasson BI
Acta Neuropathol; 2008 Jul; 116(1):37-46. PubMed ID: 18414880
[TBL] [Abstract][Full Text] [Related]
20. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.
Peelaerts W; Bousset L; Van der Perren A; Moskalyuk A; Pulizzi R; Giugliano M; Van den Haute C; Melki R; Baekelandt V
Nature; 2015 Jun; 522(7556):340-4. PubMed ID: 26061766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]